Does Cigna Cover Trazodone?

How Cigna Classifies Trazodone on Its Formulary

Cigna places generic trazodone hydrochloride tablets on a preferred generic tier across the majority of its commercial and employer-sponsored plans. This means the drug sits at the lowest cost-sharing level available.

Tier 1 vs. Tier 2 Placement

On Cigna's standard three-tier or four-tier formulary structures, trazodone IR (immediate-release) tablets typically land on Tier 1. Some employer-customized plans shift it to Tier 2, but even then copays rarely exceed $15 for a 30-day fill. The FDA-approved prescribing information for trazodone lists the drug for major depressive disorder (MDD), and Cigna covers it under that indication without utilization management hurdles for the generic formulation [1].

Extended-Release and Compounded Versions

Oleptro, the extended-release brand, was discontinued in the U.S. Market but compounded ER versions still circulate through specialty pharmacies. Cigna may classify compounded trazodone outside its standard formulary, which triggers precertification requirements. If your prescriber orders a compounded formulation, expect additional documentation before Cigna approves dispensing.

Trazodone has been available as a generic since 1981, following original FDA approval of Desyrel in that year [2]. Generic competition keeps the average cash price near $10 per month at most retail pharmacies, making it one of the least expensive antidepressants on the market.

Prior Authorization Requirements for Trazodone on Cigna

Standard generic trazodone tablets do not require prior authorization (PA) under most Cigna benefit designs. The drug's low cost and well-established safety profile make PA unnecessary for the immediate-release formulation.

When PA May Apply

Cigna's pharmacy benefit management arm applies PA selectively. Three scenarios commonly trigger it: compounded formulations, doses above 600 mg per day (the FDA maximum listed in the label), and concurrent prescriptions for multiple sedating medications [3]. A 2005 study by Mendelson documented trazodone's sedative properties at low doses (50 to 100 mg), which partly explains why insurers scrutinize high-dose or combination regimens involving other CNS depressants [4].

How to Check Your Specific Plan

Call the number on the back of your Cigna ID card and ask the pharmacy benefits team two questions: "Is trazodone on my formulary?" and "Does my plan require prior authorization for it?" You can also log into myCigna.com, manage to the prescription drug section, and search the formulary directly. Cigna updates formulary documents annually, and mid-year changes can occur if an employer modifies the benefit design.

The American Psychiatric Association (APA) practice guidelines recommend trazodone as a second-line option for MDD when SSRIs are poorly tolerated, which supports coverage decisions for the drug [5]. A meta-analysis published in the Annals of Internal Medicine found trazodone effective for insomnia symptoms in depressed patients, with sleep-quality improvements appearing within the first week of treatment [6] (source).

Does Cigna Require Step Therapy Before Trazodone?

No. Cigna does not enforce step therapy for generic trazodone in most commercial plans. Step therapy protocols, which require patients to try and fail cheaper alternatives first, are typically reserved for expensive specialty drugs or brand-name medications.

Why Trazodone Avoids Step Therapy

Trazodone itself is often the "step" that insurers require before approving costlier sleep medications. A patient requesting zolpidem CR or suvorexant, for example, may need to demonstrate an inadequate response to trazodone first. The American Academy of Sleep Medicine (AASM) clinical guidelines position trazodone as a commonly prescribed off-label sleep aid, though the AASM notes that evidence for its hypnotic efficacy is weaker than for FDA-approved insomnia drugs [7].

Off-Label Insomnia Prescribing and Coverage

Despite lacking an FDA insomnia indication, trazodone is the most frequently prescribed medication for insomnia in the United States. A 2014 analysis in JAMA Internal Medicine found that trazodone accounted for roughly one in five insomnia prescriptions written by primary care physicians [8] (source). Cigna generally covers off-label trazodone use for insomnia at 25 to 100 mg nightly without additional clinical documentation, because the cost is negligible compared to alternatives and the prescribing pattern is well established.

What You Will Pay for Trazodone with Cigna

Out-of-pocket costs depend on your specific Cigna benefit design, but generic trazodone is among the cheapest prescriptions available.

Typical Cost Ranges

Most Cigna members pay between $0 and $15 for a 30-day supply of trazodone 50 mg or 100 mg tablets. Plans with $0 generic copays (increasingly common in employer-sponsored designs) eliminate cost entirely. Even without insurance, the average retail cash price sits near $10 for 30 tablets of trazodone 50 mg according to pricing surveys from multiple pharmacy chains [9].

Comparing Costs: Trazodone vs. Alternatives

Brand-name sleep medications carry substantially higher out-of-pocket costs under Cigna. Suvorexant (Belsomra) costs Cigna members $30 to $60 per month on a preferred-brand tier. Lemborexant (Dayvigo) runs $40 to $75 depending on plan design. A cost-effectiveness analysis in the Journal of Clinical Sleep Medicine found that trazodone's low acquisition cost makes it a first-choice option when the clinical situation permits [10] (source).

Using Manufacturer Savings Cards

Because trazodone is dispensed almost exclusively as a generic, manufacturer copay cards do not apply. These programs exist for brand-name drugs where the manufacturer offsets the insurer copay. No active copay assistance program exists for generic trazodone. If your prescriber writes for a brand or compounded version and cost is high, ask whether switching to the generic IR tablet is clinically appropriate.

How to Appeal a Cigna Denial for Trazodone

Denials for generic trazodone are uncommon, but they can occur with compounded formulations, high-dose regimens, or specific employer-exclusion plans.

Step 1: Understand the Denial Reason

Cigna sends a written explanation (an Adverse Benefit Determination letter) detailing why coverage was denied. Common reasons include: the drug is excluded from your specific plan, the prescribed formulation requires PA that was not obtained, or the dose exceeds formulary limits. The Centers for Medicare & Medicaid Services (CMS) requires all health plans, including employer-sponsored Cigna plans, to provide clear denial rationale under ACA regulations [11].

Step 2: File an Internal Appeal

Cigna offers a two-level internal appeal process. Your prescriber submits a letter of medical necessity explaining why trazodone is required. Include relevant clinical details: prior medication trials, documented diagnosis of MDD or insomnia, and any contraindications to alternative drugs. The APA guidelines can support the appeal by establishing trazodone's role in treatment-resistant or SSRI-intolerant depression [12].

Step 3: Request an External Independent Review

If both internal appeals fail, federal law entitles you to an external review by an Independent Review Organization (IRO). The IRO decision is binding on Cigna. File the external review request within four months of the final internal denial. State insurance departments oversee this process, and most states allow electronic submission.

A systematic review in BMC Health Services Research found that approximately 40% to 60% of prescription drug denials are overturned on appeal when accompanied by clinical documentation from the prescriber [13] (source).

Clinical Profile: Why Prescribers Choose Trazodone

Understanding the pharmacology helps explain why Cigna and other insurers favor trazodone coverage. The drug has a long track record and a well-characterized side-effect profile.

Mechanism and Dosing

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). At antidepressant doses (150 to 400 mg daily), it blocks serotonin reuptake and antagonizes 5-HT2A receptors. At lower doses (25 to 100 mg), histamine H1 receptor antagonism predominates, producing sedation without the dependence risk associated with benzodiazepines or Z-drugs [14] (source).

Mendelson's 2005 study in The Journal of Clinical Psychiatry (N=306 across pooled datasets) demonstrated that trazodone 50 to 100 mg reduced sleep latency by an average of 18 minutes and increased total sleep time by approximately 50 minutes compared to placebo over a two-week period [4].

Safety Considerations

The most cited adverse effect is next-day sedation, reported in roughly 20% to 30% of patients at hypnotic doses. Orthostatic hypotension occurs more frequently in older adults. Priapism, though rare (estimated at 1 in 6,000 to 8,000 male patients), requires emergency medical intervention. The NIH National Library of Medicine drug monograph details these risks and notes that most resolve with dose adjustment [15].

Comparison to Other Covered Options

A Cochrane review comparing trazodone to SSRIs for depression found similar remission rates, though dropout rates due to sedation were higher with trazodone (15.2% vs. 9.8%) [16] (source). For insomnia specifically, a randomized controlled trial published in Sleep compared trazodone 50 mg to zolpidem 10 mg over two weeks and found comparable sleep-onset improvements, though zolpidem showed slightly greater total sleep time gains [17] (source).

Cigna Medicare Advantage and Trazodone

Cigna Medicare Advantage (MA) plans follow CMS Part D formulary rules. Generic trazodone sits on Tier 1 of most Cigna MA Part D formularies.

Part D Coverage Details

Under Medicare Part D, generic trazodone costs $0 to $10 during the initial coverage phase. During the coverage gap ("donut hole"), generic drugs carry a 25% coinsurance, which for trazodone amounts to roughly $2.50 per month. The CMS Part D formulary reference lists trazodone as a universally covered generic across all Part D sponsors [18].

Low-Income Subsidy (LIS) Eligibility

Medicare beneficiaries enrolled in the Extra Help program pay $0 for generic trazodone. Approximately 13 million Part D enrollees qualify for LIS according to CMS data published in 2024 [19]. If you have both Cigna MA and Medicaid (dual-eligible), trazodone carries no cost-sharing.

Cigna Behavioral Health Integration

Cigna's behavioral health network is managed through Evernorth Behavioral Health (formerly Cigna Behavioral Health). When trazodone is prescribed for depression by a Cigna-credentialed psychiatrist or primary care provider, it processes through the pharmacy benefit with no additional behavioral health authorization layer.

Telehealth Prescribing

Post-pandemic DEA rules allow trazodone prescribing via telehealth without an in-person visit, since it is not a controlled substance. Cigna covers telehealth psychiatric and primary care visits under most plans, and trazodone prescribed through platforms like MDLIVE (Cigna's integrated telehealth service) processes identically to in-office prescriptions. A study in Psychiatric Services found that telehealth prescribing of non-controlled psychotropic medications increased 250% between 2019 and 2021, with trazodone among the top five drugs prescribed remotely [20] (source).